Primary Site >> Colorectal Cancer

Gene >> DNER

  • 2016
  • 2017
  • 2018
Ref: CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.
PMID: 26752646
Ref: BET bromodomain is a novel regulator of TAZ and its activity.
PMID: 27717711
Ref: The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer.
PMID: 27678457
Ref: Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
PMID: 28576751
Ref: Anticancer Applications of Nanostructured Silica-Based Materials Functionalized with Titanocene Derivatives: Induction of Cell Death Mechanism through TNFR1 Modulation.
PMID: 29385103
Ref: Co-inhibition of BET proteins and NF-kappaB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
PMID: 29472532
Ref: ABCA1 overexpression worsens colorectal cancer prognosis by facilitating tumour growth and caveolin-1-dependent invasiveness, and these effects can be ameliorated using the BET inhibitor apabetalone.
PMID: 30098223
Ref: PES1 is transcriptionally regulated by BRD4 and promotes cell proliferation and glycolysis in hepatocellular carcinoma.
PMID: 30172011